MedTrace Logo

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer

NCT01352494 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2011-05-27

No results posted yet for this study

Summary

The purpose of this study is to assess the response of docetaxel and gemcitabine in the neoadjuvant setting in women with locally advanced breast cancer.

Conditions

  • Breast Cancer Stage II
  • Breast Cancer Stage III

Interventions

DRUG

docetaxel

docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles

DRUG

gemcitabine

gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles

Sponsors & Collaborators

  • Korean Breast Cancer Study Group

    lead OTHER

Principal Investigators

  • Young Jin Suh, M.D. Ph.D · Department of Surgery, the Catholic university of Korea, St. Vincent's hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-05-31
Completion
2015-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01352494 on ClinicalTrials.gov